{"id":342059,"date":"2024-07-02T00:00:00","date_gmt":"2024-07-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0042-biopharma-atrial-fibrillation-epidemiology-epidemiology-dashboard\/"},"modified":"2026-03-31T10:29:19","modified_gmt":"2026-03-31T10:29:19","slug":"epidcv0042-biopharma-atrial-fibrillation-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0042-biopharma-atrial-fibrillation-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Atrial Fibrillation &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of atrial fibrillation (<abbr title=\"atrial fibrillation\">AF<\/abbr>) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of <abbr title=\"atrial fibrillation\">AF<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"atrial fibrillation\">AF<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will change in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"atrial fibrillation\">AF<\/abbr> and the number of new diagnoses of <abbr title=\"atrial fibrillation\">AF<\/abbr>?<\/li>\n<li>In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of <abbr title=\"atrial fibrillation\">AF<\/abbr> and the number of new diagnoses of <abbr title=\"atrial fibrillation\">AF<\/abbr>?<\/li>\n<li>How will improvements in survival change the number of people living with a diagnosis of <abbr title=\"atrial fibrillation\">AF<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"atrial fibrillation\">AF<\/abbr>, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"atrial fibrillation\">AF<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"atrial fibrillation\">AF<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Top-line epidemiology \u2013 Total atrial fibrillation prevalent cases.<\/li>\n<li>Total prevalent cases by diagnosis scheme.<\/li>\n<li>Diagnosed prevalent cases by subtypes.<\/li>\n<li>Diagnosed prevalent cases by comorbid populations.<\/li>\n<li>Diagnosed prevalent cases by <abbr title=\"Congestive heart failure, high blood pressure, age 45 or older, diabetes, previous stroke or transient ischemic attack\">CHADS2<\/abbr> score.<\/li>\n<li>Diagnosed prevalent cases by <abbr data-abbreviation-entity=\"7885\" title=\"Congestive heart failure, high blood pressure, age 45 or older, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65-74, sex (female)\">CHA2DS2-VASc<\/abbr>\u00a0score.<\/li>\n<li>Diagnosed prevalent cases by treatment scheme<\/li>\n<li>Diagnosed incident cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-342059","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-atrial-fibrillation","biopharma-therapy-areas-cardiovascular","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/342059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/342059\/revisions"}],"predecessor-version":[{"id":575942,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/342059\/revisions\/575942"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=342059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}